Please assess the completion status of the following clinical trial:

Trial Title: Bone Marrow Mononuclear Cells vs Mesenchymal Stem Cells in Diabetic Patients With Chronic Limb Ischemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male or female, 40 years of age or over (until 85 years old)~* TcPO2 ≤ 30 mmHg.~* Diagnosis of diabetes.~* Patients with signs of critical ischemia such as (i) ulcer that does not heal, (ii) necrosis or loss of tissue, (iii) pain at rest, and (iv) intermittent claudication.~* Basal Rutherford classification stage 3 to 5.~* Non-revascularizable patients due to comorbidities and/or anatomy.~* Patients that despite revascularization (vascular surgery), have adequate distal beds to perfuse the limb.~* Ankle/brachial index less than 0.4.~* Stenosis or occlusion of the infrapatellar arteries.~Exclusion Criteria:~* Participants that do not sign the informed consent.~* Presence of osteomyelitis.~* Hemodynamic instability (MAP\<65 mmHg or vasopressor requirement).~* Any acute systemic infectious disease process.~* Severe sepsis.~* Uncontrolled coagulopathy.~* Condition of cancer.~* Use of immunosuppressive or cytotoxic drugs~* Alterations of the bone marrow that do not allow the adequate extraction of the components to be used as: acute leukemia, chronic leukemia, marrow aplasia, myelodysplastic syndrome, and myelophthisis.~* Contraindication of sedation for bone marrow aspirate.~* Patients who have suffered in a period \< six months of myocardial infarction, disease cerebrovascular or coronary intervention.~* Patients with liver failure indicated by serum transaminases (aspartate aminotransferase and alanine aminotransferase), with values twice the normal limit.~* Any acute or chronic contagious disease including hepatitis B, hepatitis C, and HIV.~* Any other comorbidity that the treating vascular surgeon considers as a contraindication to cell treatments.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Placebo group (Type: PLACEBO_COMPARATOR): Placebo group (n=10), which consisted of 15 injections of 1 mL of vehicle (1 mL saline solution with 2% of autologous serum) on periadventitial arteries in one dose at day 0.
- Auto-BM-MNC (Type: EXPERIMENTAL): Auto-BM-MNC (n=7) were obtained from diabetic patients. Fifteen injections of 7.197x106 ± 2.984x106 cells/mL each with 2% of autologous serum were periadventitial arteries administrated in one dose at day 0.
- Allo-WJ-MSCs (Type: EXPERIMENTAL): Allo-WJ-MSCs (n=7) were obtained from culturing the WJ from healthy cordon umbilical donors unrelated to the patient. Fifteen injections of 1.333x106 cells/mL each with 5% of human serum albumin serum were periadventitial arteries administrated in one dose at day 0.

Based on this trial design, predict the completion outcome and termination type (if applicable).